造血干细胞移植未能改善低二倍体急性淋巴细胞白血病儿童的不良结局:来自儿童肿瘤协作组的报告
该研究回顾性分析了2003至2011年COG AALL03B1试验中8522例B-ALL患者,低二倍体占1.5%(n=131),诱导后完全缓解率98.3%。5年无事件生存率(EFS)和总生存率(OS)分别为52.2%±4.9%和58.9%±4.8%,首次完全缓解(CR1)期造血干细胞移植(HSCT)未显著改善结局(5年EFS 57.4%±7.0% vs 47.8%±7.5%,P=.49;OS 66.2%±6.6% vs 53.8%±7.6%,P=.34)。
要点
- 低二倍体B-ALL占COG试验B-ALL患者的1.5%,5年EFS和OS分别为52.2%±4.9%和58.9%±4.8%。
- CR1期HSCT组与非移植组5年EFS无显著差异(57.4%±7.0% vs 47.8%±7.5%,P=.49)。
- 诱导末微小残留病(MRD)≥0.01%者5年EFS仅26.7%±9.3%,HSCT无显著影响。
核心结论
- 低二倍体B-ALL儿童及年轻成人结局仍差,似乎不能从CR1期HSCT获益。
- 诱导末MRD≥0.01%的患者尤其如此,这些患者亟需新的治疗策略。
研究设计与样本
- 回顾性分析2003至2011年入组COG AALL03B1试验(NCT00482352)的8522例NCI标准危和高危B-ALL患者。
- 低二倍体定义为染色体众数小于44和/或DNA指数小于0.81,由COG认证实验室检测。
- MRD由两家参考实验室采用流式细胞术集中检测。
主要发现
- 低二倍体发生率为1.5%(n=131),诱导后98.3%达到完全缓解。
- 5年EFS和OS分别为52.2%±4.9%和58.9%±4.8%。
- CR1期HSCT组5年EFS为57.4%±7.0%、OS为66.2%±6.6%,非移植组分别为47.8%±7.5%和53.8%±7.6%(P=.49和.34)。
- 诱导末MRD≥0.01%者5年EFS为26.7%±9.3%、OS为29.3%±10.1%,HSCT无显著影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Children and young adults with hypodiploid B-lymphoblastic leukemia (B-ALL) fare poorly and hematopoietic stem-cell transplantation (HSCT) is often pursued in first complete remission (CR1). We retrospectively reviewed the outcomes of children and young adults with hypodiploid B-ALL who were enrolled in recent Children's Oncology Group (COG) trials to evaluate the impact of HSCT on outcome. PATIENTS AND METHODS: Cytogenetic analyses and DNA index were performed at COG-approved laboratories, and hypodiploidy was defined as modal chromosome number less than 44 and/or DNA index less than 0.81. Minimal residual disease (MRD) was determined centrally using flow cytometry at two reference laboratories. Patients with hypodiploid ALL came off protocol therapy postinduction and we retrospectively collected details on their subsequent therapy and outcomes. Event-free survival (EFS) and overall survival (OS) were estimated for the cohort. RESULTS: Between 2003 and 2011, 8,522 patients with National Cancer Institute standard-risk and high-risk B-ALL were enrolled in COG AALL03B1 ( ClinicalTrials.gov identifier: NCT00482352). Hypodiploidy occurred in 1.5% of patients (n = 131), 98.3% of whom achieved CR after induction therapy. Five-year EFS and OS were 52.2% ± 4.9% and 58.9% ± 4.8%, respectively. Outcomes for patients undergoing CR1 HSCT were not significantly improved: 5-year EFS and OS were 57.4% ± 7.0% and 66.2% ± 6.6% compared with 47.8% ± 7.5% and 53.8% ± 7.6%, respectively ( P = .49 and .34, respectively) for those who did not undergo transplantation. Patients with MRD of 0.01% or greater at the end of induction had 5-year EFS and OS of 26.7% ± 9.3% and 29.3% ± 10.1%, respectively, and HSCT had no significant impact on outcomes. CONCLUSION: Children and young adults with hypodiploid B-ALL continue to fare poorly and do not seem to benefit from CR1 HSCT. This is especially true for patients with MRD of 0.01% or greater at the end of induction. New treatment strategies are urgently needed for these patients.
引用
- McNeer JL, Devidas M, Dai Y, et al. Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group. J Clin Oncol. 2019. PMID: 30742559. doi:10.1200/JCO.18.00884
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。